Intravesical administration of pirarubicin against superficial bladder cancer: Relationship between tumor tissue concentration and exposure time in the bladder or therapeutic effect

Experimental and Therapeutic Medicine

Volumn 2, Issue 5, 2011, Pages 901-905

  Arakawa, Maki ^a   Nakamura, Kogenta ^a   Yamada, Yoshiaki ^a   Kato, Kimihito ^b   Katsuda, Remi ^a   Tobiume, Motoi ^a   Zennami, Kenji ^a   Watanabe, Masayuki ^a   Kato, Yoshiharu ^a   Nishikawa, Genya ^a   Yoshizawa, Takahiko ^a   Aoki, Shigeyuki ^a   Taki, Tomohiro ^a   Mitsui, Kenji ^c   Honda, Nobuaki ^a   Saito, Hiroko ^a   Hasegawa, Takaaki ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Ichinomiya Municipal Hospital   (Japan)

^c Tokoname Municipal Hospital   (Japan)

Author keywords

Exposure time; Intravesical chemotherapy; Pirarubicin; Prophylactic effect against recurrence; Superficial bladder cancer; Tumor tissue concentration

Indexed keywords

PIRARUBICIN; THERARUBICIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER IRRITATION; BLADDER SURGERY; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG DETERMINATION; DRUG EFFECT; DRUG EXPOSURE; DRUG STRUCTURE; DRUG TUMOR LEVEL; FEMALE; HUMAN; HUMAN TISSUE; MALE; RECURRENT CANCER; SINGLE DRUG DOSE; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TUMOR VOLUME;

EID: 79960259186     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.315     Document Type: Article

References (27)

1. Lutzeyer W, Rubben H and Dahm H: Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 127: 250-252, 1982.
2. Herr HW, Laudone VP and Whitmore WF: An overview of intravesical therapy for superficial bladder tumors. J Urol 138: 1363-1368, 1987.
3. Miki T, Nonomura N, Kojima Y, et al: A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer. Hinyokika Kiyo 43: 907-912, 1997 (In Japanese).
4. Sylvester RJ, van der MA and Lamm DL: Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964-1970, 2002.
5. Lamm DL, Blumenstein BA, Crawford ED, et al: A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med 325: 1205-1209, 1991.
6. Witjes JA, Meijden AP, Sylvester LC, Debruyne FM, van Aubel A and Withes WP: Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacilli Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 52: 403-410, 1998.
7. Soloway MS, Sofer M and Vaidya A: Contemporary management of stage T1 transitional cell carcinoma of the bladder. J Urol 167: 1573-1583, 2002.
8. Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B and Sylvester R, Members of the European Organization for Research and Treatment of Cancer Genitourinary Group: A prospective European organization for research and treatment of cancer genitourinary group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149: 749-752, 1993.
9. Tolley DA, Parmar MK, Grigor KM, et al: The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow-up. J Urol 155: 1233-1238, 1996.
10. Rajala P, Liukkonen T, Raitanen M, Rintala E, Kaasinen E, Helle M and Lukkarinen O: Transurethral resection with perioperative instillation of interferon-α or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study-Finnbladder III. J Urol 161: 1133-1136, 1999.
11. Solsona E, Iborra I, Ricós JV, Monrós L, Casanova J and Dumont R: Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol 161: 1120-1123, 1999.
12. Zincke H, Utz DC, Taylor WF, Myers RP and Leary FJ: Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized double-blind, controlled trial. J Urol 129: 505-509, 1983.
13. Prout GR, Koontz WW, Coomms LJ, Hawkins IR and Friedell GH: Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J Urol 130: 677-680, 1983.
14. Fukushima T, Ueda T and Nakamura T: Pharmacokinetics and action mechanism of anthracyclines. Gan To Kagaku Ryoho 19: 445-450, 1992 (In Japanese).
15. Akaza H, Niijima T, Hisamatsu T and Fujigaki M: Comparative investigation on use of (2''R)-4'-O-tetrahydropyranyl-adriamycin and adriamycin as intravesical chemotherapy for superficial bladder tumors. Urology 32: 141-145, 1988.
16. Kunimoto S, Miura K, Takahashi Y, Takeuchi T and Umezawa H: Rapid uptake by cultured tumor cells and intracellular behavior of 4-O-tetrahydropyranyladriamycin. J Antibiot 36: 3123-3117, 1983 (In Japanese).
17. Okamura K, Ono Y, Kinukawa T, et al: Nagoya University Urological Oncology Group. Randomized study of single early instillation of (2''R)-4-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma. Cancer 94: 2363-2368, 2002.
18. Nakagawa S, Kojima M, Takeda H, Sugimoto K, Mikami K and Watanabe H: Short-duration bladder instillation therapy with pirarubicin for superficial bladder tumor based on pharmacodynamic study. Gan To Kagaku Ryoho 19: 1837-1877, 1992 (In Japanese).
19. Sugano O, Hatakeyama T and Kato H: Investigation of retention time of intravesical instillation therapy with pirarubicin (THP). Gan To Kagaku Ryoho 23: 1169-1174, 1996 (In Japanese).
20. Kanayama H, Yokota K, Kurokawa Y, et al: Postoperative prophylactic intravesical instillation of tetrahydropyranyl-adriamycin (THP) for superficial bladder cancer. Gan To Kagaku Ryoho 26: 651-655, 1999 (In Japanese).
21. Kuwano M, Toh S, Uchiumi T, Takano H, Kohno K and Wada M: Multidrug resistance-associated protein subfamily transporters and drug resistance. Anticancer Drug Des 14: 123-131, 1999.
22. Hasegawa S, Abe T, Naito S, et al: Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 71: 907-913, 1995.
23. Kimiya K, Naito S, Soejima T, Sakamoto N, Kotoh S, Kumazawa J and Tsuruo T: Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. J Urol 148: 441-445, 1992.
24. Naito S, Kotoh S, Omoto T, et al: The Kyushu University Urological Oncology Group: Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. Cancer Chemother Pharmacol 42: 367-372, 1998.
25. Tada Y, Wada M, Migita T, et al: Inceased expression of multidrug resistance-associated proteins in bladder cancer drug clinical course and drug resistance to doxorubicin. Int J Cancer 98: 630-635, 2002.
26. Maruyama T, Higuchi Y, Suzuki T, Qiu J, Yamamoto S and Shima H: Double short-time exposure to pirarubicin produces higher cytotoxicity against T24 bladder cancer cells. J Infect Chemother 17: 11-16, 2010.
27. Yamamoto Y, Nasu Y, Saika T, Aaeda T, Tsushima T and Kumon H: The absorption of pirarubicin instilled intravesicaly immediately after transurethral resection of superficial bladder cancer. BJU Int 86: 802-804, 2000.